T lymphocytes are critical cells involved in allergy. Here, we report that the natural tetranortriterpenoid gedunin impaired allergic responses primarily by modulating T lymphocyte functions. The intraperitoneal (i.p.) administration of gedunin inhibited pleural leukocyte accumulation triggered by intra-pleural (i.pl.) challenge with ovalbumin (OVA) in previously sensitized C57BL/6 mice; this inhibition was primarily due to the impairment of eosinophil and T lymphocyte influx. Likewise, i.pl. pre-treatment with gedunin inhibited eosinophil and T lymphocyte migration into mouse lungs 24 h after OVA intra-nasal (i.n.) instillation. Pretreatment with gedunin diminished the levels of CCL2, CCL3, CCL5, CCL11, Interleukin-5 and leukotriene B 4 at the allergic site. In vitro pre-treatment with gedunin failed to inhibit T lymphocyte adhesion and chemotaxis towards pleural washes recovered from OVA-challenged mice, suggesting that gedunin inhibits T lymphocyte migration in vivo via the inhibition of chemotactic mediators in situ. In vivo pre-treatment with gedunin reduced the numbers of CD69 + and CD25 + T lymphocytes in the pleura and CD25 + cells in the thoracic lymph nodes 24 h after OVA i.pl. challenge. In accordance, in vitro treatment of T lymphocytes with gedunin inhibited α-CD3 mAb-induced expression of CD69 and CD25, proliferation, Interleukin-2 production and nuclear translocation of NFκB and NFAT. Notably, post-treatment of mice with gedunin reverted OVAinduced lung allergic inflammation by decreasing the T lymphocyte and eosinophil counts and the levels of eosinophilotactic mediators in bronchoalveolar lavage fluid. Our results demonstrate a remarkable antiallergic effect of gedunin due to its capability to modulate T cell activation and trafficking into the airways.
Introduction
Allergy is characterized by an intense inflammatory response that involves multiple mediators and cell types. Eosinophil infiltration to sites of allergic inflammation correlates with the development of airway hyperresponsiveness and the clinical severity of allergic diseases, such as asthma [1] [2] [3] [4] . Indeed, eosinophil activation leads to the generation and release of lipid mediators and cytokines, which are crucial in the development and maintenance of the allergic response [2, [5] [6] [7] . Eosinophil trafficking from the blood to inflamed tissue during the allergic response is coordinated primarily by the eosinophilotactic mediators interleukin (IL)-5 and chemokine (C-C motif) ligand 11 (CCL11)/eotaxin. The production of these mediators is highly dependent on T lymphocytes, which also accumulate in the allergic tissue [8] [9] [10] [11] [12] [13] [14] [15] .
T lymphocytes are centrally involved in the allergic response. During the allergic response, T lymphocytes generate a wide range of cytokines and chemokines that modulate other cell populations, including eosinophils. Patients with asthma [16] [17] [18] and allergic rhinitis [19, 20] present elevated levels of the Th2 cytokines IL-4, IL-5 and IL-13 and the eosinophilotactic chemokines CCL11 and CCL5, all of which are dependent on T lymphocyte activity [13] . In this context, the impairment of T lymphocyte functions is essential for controlling the allergic response. Indeed, the inhibition of T lymphocyte accumulation in the airways of asthma patients and experimental animals ameliorates airway allergic inflammation [21] [22] [23] [24] [25] [26] and diminishes eosinophil infiltrates in the allergic tissue. Hence, impairing the production of soluble mediators that activate T lymphocytes and orchestrate their migration into the allergic tissue is a valuable strategy to control the allergic response.
We have previously described that a fraction containing tetranortriterpenoid (TNTP) compounds extracted from the seeds of Carapa guianensis Aublet (Meliaceae)-which contains gedunin as one of the compounds-presented marked anti-allergic effects in different in vivo models [27, 28] . Our results support the ethnopharmacologic use of C. guianensis in Brazil and other countries encompassing the Amazon rainforest and are in accord with the knowledge that the medicinal properties of this species correlate International Immunopharmacology 14 (2012) [82] [83] [84] [85] [86] [87] [88] [89] [90] [91] [92] [93] with the presence of TNTPs [for review see 29, 27, 28] . Using a murine model of allergic pleurisy, we have shown that this fraction of pooled TNTPs impairs allergen-induced eosinophilia, primarily due to the inhibition of IL-5 and CCL11 [28] . We have also demonstrated that pooled TNTPs inhibit the in vitro proliferation of T lymphocytes and the production of inflammatory mediators [30] .
In the present report, we investigated the potential anti-allergic effect of the TNTP gedunin contained in this fraction. We demonstrate that gedunin presents an important anti-allergic activity in in vivo models of allergic airway inflammation, which was achieved by both pre-and post-treatments with gedunin. This anti-allergic effect was shown to be mediated by the inhibition of chemotactic mediators involved in T cell and eosinophil migration. Moreover, we show that gedunin directly modulates T lymphocyte activation, which is crucial for the development and maintenance of the inflammatory allergic response.
Materials and methods

Animals
The C57BL/6 mice (18-20 g) used in this study were provided by the Oswaldo Cruz Foundation breeding unit (Rio de Janeiro, Brazil). The animals were caged with free access to food and fresh water in a room with the temperature ranging from 22 to 24°C and a 12 h light/dark cycle. The animals were housed at the Farmanguinhos experimental animal facility unit until use. All experimental procedures were performed according to The Committee on Ethical Use of Laboratory Animals of Fundação Oswaldo Cruz (FIOCRUZ, Brazil; license L-0004/08).
Materials
Endotoxin-free ovalbumin (OVA), dexamethasone, phosphate buffered saline (PBS), Tween-20, o-phenylenediamine dihydrochloride (OPD), fucoidan, ethylenedyaminetetracetic sodium salt (EDTA), percoll, sodium citrate, HEPES, bovine serum albumin (BSA), phosphate citrate buffer, 3,3'-Diaminobenzidine tetrahydrochloride hydrate (DAB) and Hank's balanced salt solution (HBSS) were purchased from Sigma Chemical Co. (St. Louis, MO, USA). Aluminum hydroxide was purchased from EMS Sigma Pharma (São Paulo, Brazil). Purified anti-murine CCL2, CCL3, CCL5 and CCL11 monoclonal antibodies (mAbs), biotinylated anti-CCL2, anti-CCL3, anti-CCL5 and anti-CCL11 mAbs and recombinant CCL2, CCL3, CCL5 and CCL11 were obtained from PharMingen (San Diego, CA, USA). The leukotriene (LT)B 4 enzyme immunoassay (EIA) kit was obtained from Cayman Chemical (Ann Arbor, MI, USA). Antimurine interleukin (IL)-2 mAb, biotinylated anti-IL-2 polyclonal antibodies (pAb), recombinant IL-2, anti-murine IL-5 mAb, biotinylated anti-IL-5 pAb, recombinant IL-5, anti-murine tumor necrosis factor-α (TNF-α) mAb, biotinylated anti-TNF-α pAb, recombinant mouse TNF-α (rmTNF-α), Peridinin-chlorophyll-protein complex (PerCP)-conjugated hamster IgG anti-murine CD3, fluorescein isothiocyanate (FITC)conjugated hamster IgG anti-murine CD11b, phycoerytrin (PE)conjugated hamster IgG anti-murine CD25, FITC-conjugated rat IgG anti-murine CD69, PerCP-conjugated IgG, PE-conjugated IgG and FITCconjugated IgG were all obtained from R&D Systems (Minneapolis, MN, USA). Fetal bovine serum (FBS) was obtained from HyClone (Logan, Utah, USA). Carboxyfluorescein diacetate-succinimidyl ester (CFSE) was obtained from Invitrogen (Carlsbad, CA, USA) Rabbit antimouse nuclear factor (NF)kB/p65 (C-20), goat anti-mouse nuclear factor of activated T cells (NFAT), biotinylated goat anti-rabbit IgG and biotinylated rabbit anti-goat IgG were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA); and streptavidin-conjugated horseradish peroxidase was purchased from Caltag Laboratories (Burlingame, CA, USA). Endotoxin-free gedunin was purchased from Gaya Chemical Corporation (Gaylordsville, CT, USA) ( Fig. 1 ). Gedunin purity (95%) was certified by thin layer chromatography by Gaya Chemical Co. and by high-speed countercurrent chromatography (HSCC) (in a model HSCCC-1000; Pharma-Tech Research Corp., Baltimore, Maryland, USA) at Farmanguinhos Natural Product Laboratory.
Treatments
Mice received an intraperitoneal (i.p.) injection of gedunin (60-500 μg/kg) diluted in sterile PBS/0.001% Tween 20 or of dexamethasone (1 mg/kg) diluted in sterile PBS 1 h prior to or 1 h after OVA stimulation. The same volume of vehicle was administered to the control groups.
Allergic pleurisy
Allergic pleurisy has been an established animal model to study the allergic response, in which serum IgE levels and tissue eosinophilia are increased, as previously reported by us and others [31] [32] [33] . For that, mice were actively sensitized by a subcutaneous (s.c.) injection of 200 μl of a mixture of OVA (50 μg) and aluminum hydroxide (5 mg). Fourteen days later, the mice were challenged with an intrapleural (i.pl.) injection of OVA (12.5 μg/cavity) diluted in sterile PBS to a final volume of 100 μl. Sensitized mice challenged with vehicle alone (saline) were used as the negative control group. Twenty-four hours after the stimulus, the mice were euthanized by excess carbon dioxide inhalation, and their thoracic cavities were rinsed with 1 ml of saline containing EDTA (10 mM), pH 7.4. Thoracic lymph nodes were harvested and mechanically dissociated into single-cell suspensions after centrifugation (400 × g for 10 min).
OPW preparation
Cell-free pleural washes recovered from OVA-challenged mice (OPW) were used as the stimulus in in vitro and in vivo assays. For OPW preparation, 24 h after i.pl. OVA injection into sensitized mice (OVA, 12.5 μg/cavity), the pleural cavities of the mice were washed with 500 μl of saline/EDTA (10 mM), pH 7.4. Sensitized mice that were injected with vehicle alone (saline) were used as the negative control group (SPW). Pleural washes recovered from mice injected with saline (SPW, n = 10) or OVA (OPW, n = 10) were pooled and centrifuged (420 ×g for 10 min at 20°C), and the cell-free supernatant was maintained at − 20°C until use. 
Lung allergic inflammation
Fourteen days after active sensitization (50 μg OVA/5 mg aluminum hydroxide in 200 μl, s.c.), the mice were boosted by the same mixture and route of administration. On days 21, 22 and 23, anesthetized mice (ketamine [35 mg/kg]/xylazine [5 mg/kg], 100 μl i.p.) received an intranasal (i.n.) dose of 100 μg OVA in 25 μl of saline solution (or saline solution alone). Twenty-four hours after the last challenge, the mice were euthanized and bronchoalveolar lavage (BAL) fluid was obtained via the tracheal cannula by gently washing with 1 ml of saline containing EDTA (10 mM), pH 7.4. This method was adapted from Fonseca et al. [34] .
Leukocyte counts
Total leukocyte counts from pleural washes, BAL and thoracic lymph nodes were determined using a Neubauer chamber, under an optical microscope, after dilution in Turk fluid (2% acetic acid). Pleural T lymphocyte counts are reported as the number of cells per cavity. The lymph node T lymphocyte counts are expressed as cells per milligram of lymphoid tissue.
Flow cytometric analysis
Leukocytes (10 6 /100 μl) were labeled with the appropriate concentration of PerCP-conjugated anti-CD3 mAb, PE-conjugated anti-CD25 mAb, FITC-conjugated anti-CD69 mAb, or PerCP-, PE-or FITCconjugated isotype antibodies for 30 min at 4°C after an incubation with rat serum to block non-specific binding. The cells were then washed with PBS/0.1% azide and surface marker analysis was performed using Cell Quest software on a FACSCalibur flow cytometer (Becton Dickinson, San Jose, CA, USA). At least 10 4 T lymphocytes were acquired per sample. All data were collected and displayed on a log scale of increasing fluorescence intensity and are presented as histograms. T lymphocyte numbers were determined after multiplying the percentage of CD3 + cells by the total number of leukocytes.
Intracellular immunostaining
After surface marker staining, cells recovered from the pleural cavities of mice were fixed with 2% paraformaldehyde at 4°C for 20 min and incubated with 0.1% saponin in PBS/0.1% azide/10% FBS. For intracellular staining of chemokines, anti-murine CCL2, CCL3 or CCL5 biotinylated antibodies were added to the cell suspension and incubated at 4°C for 30 min, followed by streptavidin-Cy-Chrome. The analysis was performed using Cell Quest software on a FACSCalibur flow cytometer (Becton Dickinson, San Jose, CA, USA). CD11b + cells within mononuclear cell gate (determined by FSC-H and SSC-H characteristics) were specifically gated, and at least 10 4 cells were acquired per sample. The counts are reported as the percentage of positive cells.
Quantification of inflammatory mediators
CCL2/MCP-1, CCL3/MIP-1α, CCL5/RANTES, CCL11/eotaxin, IL-5 and IL-2 levels were evaluated in cell-free pleural washes recovered from sensitized C57BL/6 mice 24 h after OVA stimulation (12.5 μg/cavity, OPW) or in the supernatant of α-CD3-stimulated T lymphocytes by enzyme-linked immunosorbent assay (ELISA) using matched antibody pairs from R&D Systems, according to the manufacturer's instructions. IL-5, CCL5 and CCL11 were evaluated in BAL fluid by cytometric beads array (CBA, BD Pharmingen) on a FACSCalibur (BD) according to the manufacturer's instructions. The LTB 4 levels were measured by EIA in 24 h-OPW using a commercial kit (Cayman Chemical, Ann Arbor, MI) according to the manufacturer's instructions. The results are expressed as pg/ml or ng/ml based on a standard curve.
Recovery of splenic T lymphocytes
Spleens recovered from euthanized C57BL/6 mice were dissected and macerated in RPMI 1640 medium with Ca 2+ /Mg 2+ containing 30 mM HEPES and 0.25% BSA, pH 7.4. The tissue was centrifuged (420 ×g for 10 min at 20°C), and the pellet was resuspended in 5 ml of assay buffer (RPMI 1640 enriched with 10% FBS, 2 mM L-glutamine, 25 μg/ml gentamicin and 50 μM β-mercaptoethanol, pH 7.4). After centrifugation (200 ×g for 10 min at 20°C), the leukocyte pellet was resuspended in 3 ml of assay buffer and submitted to a Histopaque-1077 gradient (400 ×g for 30 min at 20°C). T lymphocytes were isolated using a T cell enrichment column (R&D Systems, Minneapolis, MN, USA) (>85% of CD3 + T lymphocytes). The viability of the T cells was determined by trypan blue exclusion under light microscopy (>95%).
Endothelial cell culture
The murine thymic endothelioma cell line tEnd.1 was grown in RPMI 1640 supplemented with 10% FBS containing 25 μg/ml of gentamicin. Adherent cells were detached by 5-min incubation in 4°C trypsin/EDTA solution, washed and counted under a light microscope.
Cytotoxicity assay
The cytotoxicity of gedunin was determined in T lymphocytes recovered from C57BL/6 mouse spleens. Viable cells were seeded in a flat-bottomed 96-well plate (2 × 10 6 cells/well) and cultured for 1 h (in 5% CO 2 at 37°C). The cells were cultured in the presence of different concentrations of gedunin (10 to 200 μM) for 20 h and incubated with a solution containing MTT [3-(4,5-dimethylthiazol-2-yl)-2,5diphenyl tetrazolium bromide] (5 mg/ml in saline; 22.5 μl/well) for 4 h. The supernatant was discarded, and dimethyl sulfoxide (DMSO; 150 μl/well) was added for solubilization of the formazan crystals. The absorbance was measured at 540 nm (SpectraMax M5, Molecular Devices, USA). The compound concentrations that induced ≥ 10% cell death were considered cytotoxic and were not used in the biological assays (Table 1) , as previously described [30] .
Cell adhesion assay
tEnd.1 cells were cultured in RPMI 1640 medium supplemented with 10% heat-inactivated FBS, 2 mM L-glutamine, 100 IU/ml penicillin, and 100 μg/ml streptomycin. These cells were incubated at 37°C in a humidified incubator containing 5% CO 2 and plated onto 24-well culture chambers (10 4 cells/well) (Nunc, Rochester, NY, USA) for 24 h. Before each experiment, the tEnd.1 cells were stimulated with recombinant mouse TNF-α (10 ng/ml) for 4 h. T lymphocytes recovered from naïve C57BL/6 mice were pre-treated with fucoidan (25 μg/ml) or gedunin (100 μM, 1 h) and then allowed to adhere to the tEnd.1 cultures (50 T lymphocytes/tEnd.1) for 1 h. Non-adherent cells were gently washed away with phosphate-buffered saline (PBS), and the remaining cells were subsequently fixed in ethanol, stained with 
Chemotaxis assay
T lymphocytes recovered from naïve C57BL/6 mouse spleens were resuspended in RPMI 1640 supplemented with 10% FBS and assayed in a 48 well micro chemotaxis chamber (Neuroprobe Inc., Cabin John, MD, USA). The bottom wells of the chamber were filled with 28 μl of OPW or SPW, whereas the upper wells were filled with T lymphocytes (10 5 cells; 50 μl) previously treated with gedunin (100 μM for 1 h). The bottom and upper cells were separated by a 3 μm polycarbonate filter (Nuclepore, Pleasanton, USA). The chamber was maintained in a humidified incubator with 5% CO 2 at 37°C for 2 h. The number of migrated cells was estimated under light microscopy. Chemotaxis was calculated and expressed as the mean number of migrated cells in five random high-power fields (HPFs) per well (in quadruplicate) [35] .
In vitro stimulation of T lymphocytes
Anti-CD3 mAb (10 μg/ml) was placed in each well of a 96 well plate (Costar, Cambridge, MA, USA) at room temperature for 4 h. T lymphocytes recovered from naïve C57BL/6 mice were incubated with gedunin (100 μM), vehicle (DMSO 0.5%) or dexamethasone (5 nM) for 1 h and subsequently cultured in the anti-CD3 mAb-coated wells at a concentration of 10 5 cells/well in RPMI 1640 medium supplemented with 10% FBS (at 5% CO 2 and 37°C). After 24 h, the T cells were recovered for flow cytometry and western blot analysis.
For proliferation assays, another set of cells was labeled with CFSE (1 μM/4 × 10 7 cells) and stimulated with the anti-CD3 mAb for 72 h. After incubation, the cells were stained for surface markers, and cell division was assessed by the percentage of CFSE + high cells (0 h) compared to CFSE + low cells (72 h) as assessed by flow cytometry and gated according to FL-1 intensity. The analyses were performed using Cell Quest software on a FASCalibur flow cytometer (Becton Dickinson, San Jose, CA, USA). At least 10 4 gated CD3 + T lymphocytes were acquired per sample.
Preparation of nuclear extracts and immunoblotting
Nuclear extracts were obtained from T lymphocytes previously treated with gedunin (100 μM for 1 h at 37°C and 5% CO 2 ) and stimulated with anti-CD3 mAb (10 μg/ml for 24 h) in vitro. Cells were lysed in ice-cold buffer A (10 mM HEPES, pH 7.9; 10 mM KCl; 0.1 mM EDTA; 0.1 mM EGTA; 1 mM dithiothreitol and 0.5 mM PMSF), and after 15 min of incubation on ice, Nonidet P-40 (NP-40) was added to a final concentration of 0.5% (v/v). Nuclei were collected by centrifugation (14,000 g for 5 min at 4°C). The nuclear pellet was suspended in ice-cold buffer C (20 mM HEPES, pH 7.9; 400 mM NaCl; 1 mM EDTA; 1 mM EGTA; 1 mM dithiothreitol; 1 mM PMSF; 1 mg/ml pepstatin; 1 mg/ml leupeptin; and 20% glycerol [v/v]) and incubated for 30 min. Nuclear proteins were collected (supernatant after centrifugation at 14,000 ×g for 10 min at 4°C). The total protein content in the nuclear extracts was determined by the Bradford method. The cell lysates were denatured in Laemmli sample buffer (50 mM Tris-HCl, pH 6.8; 1% sodium dodecyl sulfate [SDS]; 5% 2-mercaptoethanol; 10% glycerol and 0.001% bromophenol blue) and heated at 95°C for 3 min. The samples (10 μg of total protein) were resolved by 12% SDS-polyacrylamide gel electrophoresis (PAGE) and the proteins were transferred to nitrocellulose membranes (Hybond-C Pure, Amersham Pharmacia Biotech, San Francisco, CA, USA). The membranes were blocked with Tween-PBS (0.5% Tween-20) containing 2% BSA and probed with the specific primary monoclonal antibodies anti-NFAT and anti-NFκB/p65 (1:500, Santa Cruz, CA, USA). After extensive washing in Tween-PBS, the nitrocellulose membranes were incubated with an anti-goat or an antirabbit IgG biotin-conjugated antibody (1:1000; Sigma) for 1 h, followed by streptavidin-conjugated horseradish peroxidase (1:1000; Caltag Laboratories, Burlingame, CA, USA). Immunoreactive proteins were visualized by 3,3′-diaminobenzidine (DAB, Sigma) staining. The bands were quantified by densitometry, using ImageJ (public domain) software programs.
Statistical analysis
The data are reported as the mean± standard error of the mean (SEM) and were statistically analyzed by analysis of variance (ANOVA), followed by the Student-Newman-Keuls test or Student's t-test. Values of p ≤ 0.05 were regarded as significant.
Results
Gedunin pre-treatment inhibits leukocyte migration during allergic airway inflammation
The i.pl. injection of OVA (12.5 μg/cavity) induced an intense accumulation of total leukocytes in the pleural cavity of C57BL/6 mice, due to the migration of mononuclear cells and eosinophils ( Fig. 2A-C) . Pre-treatment with gedunin (from 60 to 500 μg/kg, i.p.) revealed that the highest dose administered was able to inhibit the total leukocyte and eosinophil accumulation, but failed to inhibit the migration of mononuclear cells. Dexamethasone pre-treatment (1 mg/kg, i.p.), which was used as a reference drug, diminished the numbers of all cell populations. Importantly, the range of gedunin doses used in this experiment was determined based on a previous in vivo dose response experiment (performed on a log scale from 50 μg/kg to 50 mg/kg of gedunin, i.p.); the range of 60 to 500 μg/kg was chosen to be further assayed (Supplemental Fig. 1A ). OVA instillation (100 μg, i.n.) also triggered an accumulation of total leukocyte, mononuclear cells and eosinophils in the lungs of previously sensitized mice ( Fig. 2D-F) . Similar to its effect on allergic pleurisy, i.p. pretreatment with gedunin diminished OVA-induced total leukocyte and eosinophil counts in BAL fluid recovered within 24 h.
Among pleural leukocytes, OVA challenge triggered an intense influx of CD3 + T lymphocytes into the mouse pleural cavities and lungs ( Fig. 3A-B ), which was also significantly inhibited by pre-treatment with gedunin (500 μg/kg) or dexamethasone (1 mg/kg, i.p.) 1 h prior to challenge. Representative dot plots showing the percentage of CD3 + T lymphocytes among total leukocytes are displayed in the right panel.
Gedunin pre-treatment inhibits the production of chemotactic mediators at the allergic site
To evaluate whether gedunin reduced the in vivo migration of eosinophils and T lymphocytes by inhibiting the production of chemotactic mediators at the inflammatory site, the levels of CCL2, CCL3, CCL5, CCL11, IL-5 and the lipid mediator LTB 4 were evaluated in pleural washes recovered 24 h after OVA challenge (12.5 μg/cavity). OVA challenge triggered increased production of these mediators, whereas pre-treatment with gedunin (500 μg/kg, i.p.) significantly reduced the levels of all of the evaluated mediators ( Fig. 4A-F) .
Resident macrophages are known to be a major source of lymphotactic chemokines in the mouse pleura during the allergic response [31] . We therefore investigated by intracellular staining whether gedunin pre-treatment modulates chemokine production by pleural macrophages recovered from the mouse pleura 6 h after OVA challenge, which is a time point at which T lymphocyte and eosinophil numbers are not significantly increased. As shown in Fig. 4G , OVA challenge induced the production of CCL2, CCL3 and CCL5 by CD11b + macrophages, and this phenomenon was reduced by gedunin pre-treatment. These results show that the inhibition of T lymphocyte accumulation by gedunin depends, at least in part, on the reduction of 5 . Effects of gedunin on T lymphocyte adhesion to endothelial cells (A). T lymphocytes recovered from C57BL/6 mice were pre-incubated for 1 h with medium, fucoidan or gedunin and allowed to adhere to previously stimulated tEnd.1 cells (50 T lymphocytes/tEnd.1) for 1 h. Fucoidan was used as the positive control. Adhesion was quantified by an association index calculated as described in Materials and methods. The effect of gedunin on in vitro T cell chemotaxis (B). Lymphocytes were pre-incubated with gedunin for 1 h and allowed to migrate towards OPW for 2 h in a chemotaxis chamber. The migrated cells were counted under light microscopy. The effects of gedunin on OPW-induced in vivo T lymphocyte influx into mouse pleural cavities (C). C57BL/6 mice were pre-treated with gedunin 1 h before the challenge with OPW (i.pl.). T lymphocyte counts were assessed 24 h after OPW injection. * indicates statistically significant differences (p ≤ 0.05) between the non-stimulated and stimulated groups. chemotactic mediators produced by resident macrophages in the allergic tissue.
Gedunin fails to inhibit T lymphocyte adhesion and chemotaxis in vitro
Because T lymphocytes are centrally involved in the modulation of other cell populations that participate in the allergic response, the direct effect of gedunin on T lymphocytes was assessed. The pre-incubation of T lymphocytes with gedunin (100 μM, 1 h before the stimulus) failed to inhibit their adhesion to rmTNF-α-primed endothelial cells (Fig. 5A) . In contrast, pre-treatment with fucoidan, a carbohydrate that blocks selectins, inhibited T cell adhesion to endothelial cells. In accord with these data, the pre-incubation of T lymphocytes with gedunin (100 μM, 1 h before the stimulus) failed to impair T lymphocyte chemotaxis towards cell-free pleural washes recovered from OVA-challenged mice (OPW), which contains chemotactic mediators (as shown in Fig. 3) (Fig. 5B) . Pre-incubation of cells with DMSO did not induce any effect on T lymphocyte adhesion or chemotaxis (data not shown).
OPW has been shown to trigger leukocyte migration when injected into mouse pleural cavities [36] . To confirm whether the lack of response by T cells to gedunin pre-treatment in vitro was due to a direct effect involving adhesion molecules or cell motility pathways, we performed an in vivo adoptive transfer of OPW into gedunin pre-treated mice (500 μg/kg, i.p.). As expected, OPW i.pl. injection triggered a significant increase in CD3 + T lymphocyte numbers in the mouse pleural cavities compared with mice injected with cell-free pleural washes recovered from saline-injected mice (SPW) (Fig. 5C ). In vivo pre-treatment with gedunin (500 μg/kg, i.p.) failed to inhibit OPW-induced CD3 + T lymphocyte accumulation. Taken together, these results suggest that gedunin does not prevent T cell adhesion or mobilization towards chemotactic mediators in vivo.
Gedunin modulates CD69 + and CD25 + expression by T lymphocytes in vivo
Flow cytometric analysis showed that OVA i.pl. challenge (12.5 μg/cavity) triggered increased percentages of CD3 + T lymphocytes expressing CD69 and CD25 (Fig. 6A-B ) 24 h after stimulation. Pre-treatment with gedunin (500 μg/kg, i.p.) reduced the percentage of pleural CD3 + T lymphocytes expressing these two surface molecules, as did pre-treatment with dexamethasone (1 mg/kg, i.p.).
OVA i.pl. challenge induced an increase in T lymphocyte numbers in mouse thoracic lymph nodes at 24 h after stimulation, which was inhibited by pre-treatment with gedunin or dexamethasone (Fig. 6C ). These cells also presented an activated phenotype by expressing CD25 and CD69 ( Fig. 6D and data not shown) . Pre-treatment with gedunin was able to diminish the percentage of CD3 + CD25 + lymphocytes recovered from the thoracic lymph nodes (Fig. 6D) ; however, no changes in CD69 expression were observed (data not shown).
Gedunin modulates T lymphocyte activation in vitro
The in vitro stimulation of T lymphocytes with α-CD3 mAb (10 μg/ml) triggered an increase in the percentages of CD69 + and CD25 + T lymphocytes, which was reduced by pre-incubation with gedunin (100 μM for 1 h before stimulation) (percentages are demonstrated in representative histograms in Fig. 7A-B) . Gedunin pretreatment also reduced the mean fluorescence intensity (MFI) of CD69 and CD25 (Fig. 7A-B) , which is demonstrated in representative histograms of CD69 and CD25 expression, respectively. Pretreatment with dexamethasone (Dexa; 5 nM) also diminished CD69 and CD25 expression. The incubation of T lymphocytes with DMSO (0.5%) did not induce any change in CD25 and CD69 expression (data not shown). In accord with these data, gedunin pretreatment blocked α-CD3 mAb-induced T lymphocyte proliferation within 72 h as assessed by CFSE staining (Fig. 7C ) and blocked IL-2 production (Fig. 7D) .
To investigate whether the effect of gedunin on T lymphocyte activation correlated with modulation of transcriptional factors, the protein levels of NFAT and NFκB/p65 were determined by western blot analysis in nuclear extracts of α-CD3 mAb-stimulated T lymphocytes that were pre-treated or not pre-treated with gedunin. Fig. 7E shows that α-CD3 mAb stimulation enhanced the levels of NFAT and NFκB/p65 in T cell nuclei (lane 2) compared to nonstimulated lymphocytes (lane 1). The translocation of NFAT and NFκB/p65 was significantly inhibited by dexamethasone (5 nM) and by gedunin (100 μM) pre-treatment (lanes 3 and 4, respectively). Densitometric analysis of the bands is shown in the graphs below (Fig. 7E) . These results demonstrate that, even though gedunin does not inhibit cell mobilization, it directly modulates multiple features of T lymphocyte activation.
Post-treatment with gedunin inhibits lung allergic inflammation
The post-treatment of mice with gedunin (500 μg/kg i.p., 1 h after antigenic challenge) was able to revert OVA-induced (100 μg, i.n.) parameters of lung allergic inflammation, including decreased T lymphocyte and eosinophil counts in BAL fluid (Fig. 8A-B ). Similar to the results obtained with pre-treatment, post-treatment with gedunin also diminished the levels of eosinophilotactic mediators in the BAL, as did dexamethasone (Fig. 8C-E) . These results suggest that gedunin might present therapeutic benefits for the treatment of airway inflammatory diseases by modulating T lymphocyte activation.
Discussion
T lymphocytes are crucial for immunity against allergen-induced diseases in atopic individuals and experimental animals [reviewed in 37] . Here, we show that the natural TNTP gedunin inhibits allergic responses primarily by modulating T lymphocyte functions and inhibiting allergic eosinophilia.
Using two different models of airway allergic inflammation affecting the pleura and lungs of sensitized mice, we demonstrate that gedunin presents a remarkable anti-allergic effect that is comparable to dexamethasone. Noteworthy, it has been previously published that gedunin did not trigger toxic effects (including alterations in body weight, organ weight and liver enzyme levels) when administrated via different routes into mouse [38, 39] . When administered by either intraperitoneal or oral (Supplemental Fig. 1A, B) routes, gedunin was able to inhibit leukocyte migration to challenged tissue and to reverse the already established airway inflammation. Notably, the antiallergic property of gedunin seems to require the modulation of T cell functions. The first evidence of this requirement came from the ability of gedunin to inhibit the generation of chemokines and lipid mediators known to recruit and activate T lymphocytes in the tissue (and consequently, to reduce T cell infiltrates); furthermore, gedunin was able to directly inhibit T cell functions.
T lymphocyte migration towards a chemotactic gradient is a multistep process that is precisely regulated by interactions of adhesion molecules with their cognate receptors expressed on vascular endothelium. Chemokines, such as CCL2, CCL3, CCL5 and LTB 4 are important mediators of T cell influx into sites of inflammation, including the airways [40] [41] [42] [43] [44] , in which their production increases during allergic responses, such as asthma [13, [44] [45] [46] . In vivo pretreatment with gedunin reduced the in situ production of these mediators; however, this pre-treatment failed to interfere with T lymphocyte adhesion to endothelial cells and chemotaxis. This assumption was reinforced by the finding that the i.pl. injection of OPW (which contains lymphotactic mediators, including CCL2, CCL3, CCL5 and LTB 4 ) into gedunin-pre-treated mice induced pleural accumulation of T lymphocytes to the same extent as in non-treated OPW-injected mice. Therefore, gedunin inhibits in vivo T cell migration due to the inhibition of chemotactic mediators in situ but not due to lymphocyte-endothelium interactions. By inhibiting the generation of lymphotactic mediators, the anti-allergic effect of gedunin seems to occur primarily via the impairment of T cells.
In addition to preventing T lymphocyte influx by blocking the production of mediators with lymphotactic activity by resident macrophages, gedunin also inhibits key parameters of T cell activation, such as the expression of CD69 and CD25 molecules, proliferation, production of IL-2 and translocation of the transcriptional factors NFκB and NFAT. It is important to note that these effects were observed in vitro, but gedunin treatment also resulted in diminished numbers of activated T lymphocytes in draining lymph nodes and in the allergic tissue. During allergic responses, the number of T cells increase in the lymph nodes, as a consequence of antigen presentation and clonal expansion, which is followed by the migration of antigen-specific T lymphocytes into the inflamed site [47, 48] . Resident T cells are activated at the site of allergen deposition and mediate the local response to allergen, which is amplified by the arrival of new T lymphocytes in the target tissue [49] [50] [51] . Challenged mice treated with gedunin presented similar numbers of CD25 + (sal: 1.14 ± 0.42 × 10 4 cells; OVA: 3.00 ± 0.9 × 10 4 cells; gedunin: 1.64 ± 0.7 × 10 4 cells; n = 6 in each group) and CD69 + T lymphocytes (sal: 0.26 ± 0.09 × 10 4 cells; OVA: 0.79 ± 0.02 × 10 4 cells; gedunin: 0.40 ± 0.09 × 10 4 cells; n = 6 in each group) in the pleura of naïve mice, which suggests that either resident or newly arrived T lymphocytes are not activated. Therefore, the inhibition of T cell activation by gedunin treatment, both in the pleura and in the draining thoracic lymph nodes of challenged mice, is noticeable. In the draining lymph nodes, gedunin treatment reduced the number of CD3 + T lymphocytes and of CD25 + CD3 + cells, suggesting that in vivo blockade of T cell activation and expansion in secondary lymphoid organs by the TNTP might occur. The hypothesis that treatment with gedunin affects T cell proliferation in vivo is supported by the finding that gedunin inhibited IL-2 production by α-CD3-stimulated T lymphocytes in vitro. IL-2 is a major cytokine that is involved in the proliferation and differentiation of T lymphocytes and is crucial for clonal expansion [52] . Such an effect seems tightly correlated with the finding that gedunin blocked the nuclear translocation of transcription factors required for cellular activation, among which NFκB and NFAT can be highlighted [53] . NFκB and NFAT regulate the expression of many genes involved in inflammation, including IL-2 [53] . NFAT is a transcription factor that is predominantly found in T lymphocytes and regulates the expression of several cytokines (such as IL-2, IL-4 and IL-5), by interacting with AP-1 and forming a transcriptional complex. As demonstrated for corticosteroids [54, 55] , gedunin also inhibited nuclear translocation of NFAT and NFκB. Through this inhibition, gedunin blocked the synthesis of IL-2 and consequently the upregulation of CD25 (α-chain of IL-2 receptor), this relationship has been shown to occur in a positive loop [56] [57] [58] . By blocking the nuclear translocation of these two important transcription pathways, attention is brought to the anti-inflammatory effect of gedunin.
Eosinophilia is a common manifestation of late-phase allergic inflammation and has been correlated with tissue damage. Eosinophil recruitment to an allergic site is coordinated by the generation of chemotactic mediators, primarily T lymphocytes and macrophages [8] [9] [10] [11] [12] [13] [14] [15] . Glucocorticoids, such as dexamethasone, have been extensively used to treat allergic diseases such as asthma. Glucocorticoid induction of eosinophil apoptosis has been proposed as a key mechanism to reduce tissue and circulating eosinophil numbers [59] [60] [61] [62] [63] . Our results clearly demonstrate that gedunininduced eosinophil arrest is a result of the impairment of the T cell-dependent eosinophilotactic mediators IL-5, CCL11 and CCL5, even though gedunin also presents direct effects on isolated eosinophils (impairing chemotaxis), as we have previously demonstrated [30] . The ability of gedunin to revert eosinophil accumulation in the lungs might also be a result of the arrested production of eosinophilotactic mediators because, as our group has demonstrated, gedunin does not induce eosinophil death in vitro [30] .
Notably, gedunin from C. guianensis and other species has been demonstrated (by us and other authors) to exhibit immunomodulatory, anti-malarial and anti-cancer activities [30, [64] [65] [66] . The anti-proliferative activity of gedunin observed against tumor cell lines has been demonstrated to be mediated through modulation of heat shock protein 90 (HSP90) [67, 68] . Indeed, the mechanism of action of gedunin has been well established to be mediated by modulation of HSP90 [69] , which is a chaperone involved in folding and conformational regulation of several client proteins [70] . In addition to their benefits against cancer, HSP90 inhibitors can be useful as anti-inflammatory compounds; accumulating evidence has suggested a pro-inflammatory role of HSP90 in several experimental models of inflammation, including lung inflammation [71] [72] [73] [74] [75] [76] . In vivo treatment with HSP90 inhibitors has been shown to prevent the activation of transcriptional factors, the production of various inflammatory mediators and leukocyte activation and migration in vitro and in vivo [74] . Therefore, the anti-allergic and immunomodulatory effects of gedunin are likely to be a consequence of HSP90 inhibition, which correlates well with the pleiotropic effects of gedunin that are similar to those described for HSP90 inhibitors; these effects include the inhibition of cell proliferation, NFκB translocation, chemokine production and accumulation of leukocytes in the airways. This correlation will be soon addressed in further studies.
Taken together, our results demonstrate a remarkable antiallergic effect of gedunin due to its ability to modulate T lymphocyte activation and trafficking into the airways. In addition, these data highlight the importance of further study of the druggability and pharmacophoric properties of gedunin and bring to light the knowledge that gedunin might represent a potential therapeutic tool to suppress allergic features and control allergic diseases.
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